PAS
MCRB icon

Point72 Asia (Singapore)’s Seres Therapeutics MCRB Stock Holding History

Point72 Asia (Singapore)’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,249
Closed -$42.5K – 1083
2024
Q3 		$42.5K Sell
2,249
-4,133
-65% -$83.8K 0.01% 721
2024
Q2 		$92.4K Buy
+6,382
New +$106K 0.02% 509
2024
Q1 		– Sell
-143
Closed -$4K – 1165
2023
Q4 		$4K Buy
+143
New +$3.75K ﹤0.01% 540

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asia (Singapore)'s MCRB Position: Q4 2024 in Review

Point72 Asia (Singapore) sold out of Seres Therapeutics (MCRB) in Q4 2024, closing a stake of 2,249 shares — an estimated $42.5K sold.

Point72 Asia (Singapore) first reported a position in MCRB in Q4 2023 and held it in 3 quarters. The position peaked at $92.4K in Q2 2024. 69 funds tracked by Wall St. Rank hold MCRB as of Q4 2024.

  • Point72 Asia (Singapore) reported no remaining Seres Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 2,249 Seres Therapeutics shares in Q4 2024, an estimated $42.5K.
  • Point72 Asia (Singapore) first reported a position in Seres Therapeutics in Q4 2023 and held it in 3 quarters.
  • Point72 Asia (Singapore)'s Seres Therapeutics position peaked at $92.4K in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q4 2024, filed 14 Feb 2025.